Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide versus enzalutamide + radium-223 in bone-metastatic castration-resistant prostate cancer
2014-001787-36Phase 3Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in prostate cancer (PCa) comparing Enzalutamide with Enzalutamide + Xofigo (2 arms). Primary endpoint: Radiological progression-free survival. Started Jun 2015; status: active.
02
Drugs
enzalutamideradium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-001787-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001787-36.